Navigation Links
WuXi PharmaTech Congratulates the 2010 Nobel Laureates in Chemistry
Date:10/10/2010

SHANGHAI, Oct. 10 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today extended its congratulations to Dr. Richard Heck, Dr. Ei-ichi Negishi, and Dr. Akira Suzuki on winning the 2010 Nobel Prize in Chemistry. The prize was awarded for the development of palladium-catalyzed cross coupling, which has vastly improved the ability of chemists to create sophisticated chemical compounds. Dr. Negishi spoke at WuXi headquarters in July in the company's Science Seminar Series.

Dr. Negishi graduated from the University of Tokyo in 1958 and did his internship at Teijin Ltd., a Japanese pharmaceutical and chemical company. He earned a Ph.D. from the University of Pennsylvania in 1963 under the supervision of Dr. Allan Day. In 1966, he became a postdoctoral researcher at Purdue University, and he served as assistant to Nobel laureate Dr. Herbert Brow beginning in 1968. He was appointed assistant professor of chemistry at Syracuse University in 1972 and full professor at Purdue University in 1979. Dr. Negishi is the author or co-author of more than 375 papers, 30 essays, and two books.

WuXi scientists were highly impressed by Dr. Negishi's lectures in July, titled "Evolution of the Pd-Catalyzed Cross-Coupling for C-C Bond Formation: Complementary with the Grignard Chemistry" and "Zirconium-Catalyzed Asymmetric Carboalumination of Alkenes." The WuXi PharmaTech Science Seminar Series is a monthly program that invites the world's top scientific minds and leaders in the pharmaceutical industry to speak to the company's scientists. The program aims to keep them informed about the latest developments in a broad range of topics in pharmaceutical research and development.

"Congratulations to Dr. Negishi, Dr. Heck, and Dr. Suzuki on w
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
2. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
6. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
7. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
8. WuXi PharmaTech Announces Third Quarter 2008 Results
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
11. Pharmatech 2.0: Introducing Pharmatech Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... WYE ),announced that, at a meeting today, its Board ... share repurchase program,that authorizes the Company to buy back ... is inclusive of approximately $1.2 billion in,repurchases already executed ... may be suspended for periods or discontinued at any ...
... ZMH ; SWX: ZMH) today announced that it ... an ongoing federal investigation into its,financial relationships with consulting ... into a Deferred Prosecution,Agreement, will pay a civil settlement ... by a federal monitor appointed by the U.S. Department,of ...
... are fruits of strategic plan, WATERTOWN, Mass., ... and discovery, Boston Biomedical Research Institute, an independent,not-for- ... has,recruited seven new scientists, a 23% increase in ... scientists are the fruits of a three-year,strategic planning ...
Cached Biology Technology:Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend 2Zimmer Announces Settlement of Federal Investigation 2Zimmer Announces Settlement of Federal Investigation 3Zimmer Announces Settlement of Federal Investigation 4New Scientists Boost Disease-based Research at Boston Biomedical Research Institute 2New Scientists Boost Disease-based Research at Boston Biomedical Research Institute 3
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... study in Botswana, Harvard School of Public Health researchers ... resource-poor settings, who receive antiretroviral (ARV) therapy, can achieve ... fully supported health care delivery system and infrastructure help ... 2005 issue of the Journal of Acquired Immune Deficiency ...
... of researchers led by scientists at Memorial Sloan-Kettering Cancer Center ... in early stage clinical trials -- work best in patients ... that plays a central role in the growth and survival ... patients with melanoma and in a minority of patients with ...
... to research reported this week in Current Biology, tsunami ... the 2004 Sumatra-Andaman earthquake was occasionally spectacular, but surprisingly ... misuse in the region. , Less than 100 ... team of ecologists from James Cook University, the Wildlife ...
Cached Biology News:New Therapeutic Target Identified In Inherited Brain Tumor Disorder 2Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2
... peptide-1(7-36) amide (GLP-1), C-terminal reactive. Cross-reacts ... <0.1% cross reactivity with the unamidated ... related peptides such as hGLP-2, glucagon, ... species. GLP-1 is identical in all ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: